Creative Medical Technology Holdings, Inc.(CELZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CELZ Creative Medical Technology Holdings, Inc.

Pre-Mkt 05-05 08:44:59 EDT

2.17

-0.07

-3.12%

盘前2.11

-0.06-2.76%

07:00 EDT

High2.22	Low2.16	Vol33.49K
Open2.20	D1 Closing2.24	Amplitude2.67%
Mkt Cap8.02M	Tradable Cap7.01M	Total Shares3.70M
T/O73.60K	T/O Rate1.04%	Tradable Shares3.23M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"CELZ","market":"US","secType":"STK","nameCN":"Creative Medical Technology Holdings, Inc.","latestPrice":2.17,"timestamp":1777924800000,"preClose":2.24,"halted":0,"volume":33492,"hourTrading":{"tag":"盘前","latestPrice":2.11,"preClose":2.17,"latestTime":"07:00 EDT","volume":74,"amount":156.14,"timestamp":1777978802878,"change":-0.06,"changeRate":-0.02765,"amplitude":0},"delay":0,"changeRate":-0.031250000000000125,"floatShares":3229400,"shares":3696700,"eps":-2.52,"marketStatus":"Pre-Mkt","change":-0.07,"latestTime":"05-05 08:44:59 EDT","open":2.2,"high":2.2199,"low":2.16,"amount":73602.43785,"amplitude":0.026741,"askPrice":2.38,"askSize":100,"bidPrice":1.92,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.52,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1777987800000},"marketStatusCode":1,"adr":0,"exchange":"NASDAQ","adjPreClose":2.17,"preHourTrading":{"tag":"盘前","latestPrice":2.11,"preClose":2.17,"latestTime":"07:00 EDT","volume":74,"amount":156.14,"timestamp":1777978802878,"change":-0.06,"changeRate":-0.02765,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":2.17,"preClose":2.17,"latestTime":"18:04 EDT","volume":22,"amount":47.53,"timestamp":1777932277944,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.37798794629890714},"requestUrl":"/m/hq/s/CELZ/tweets","defaultTab":"tweets","newsList":[{"id":"2631815015","title":"Creative Medical knee data ‘highly positive,’ says Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2631815015","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631815015?lang=en_us&edition=fundamental","pubTime":"2026-04-28 23:53","pubTimestamp":1777391594,"startTime":"0","endTime":"0","summary":"Roth Capital analyst Jonathan Aschoff says Creative Medical (CELZ) this morning announced “highly positive” results from its pilot study of Ultraso...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/creative-medical-knee-data-highly-positive-says-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/creative-medical-knee-data-highly-positive-says-roth-capital-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CELZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630838875","title":"Creative Medical reports pilot study of Ultrasome meets priamry endpoint","url":"https://stock-news.laohu8.com/highlight/detail?id=2630838875","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630838875?lang=en_us&edition=fundamental","pubTime":"2026-04-28 21:57","pubTimestamp":1777384656,"startTime":"0","endTime":"0","summary":"Creative Medical (CELZ) announced results from its pilot study of Ultrasome, the company’s cell-free regenerative therapy for the treatment of oste...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/creative-medical-reports-pilot-study-of-ultrasome-meets-priamry-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/creative-medical-reports-pilot-study-of-ultrasome-meets-priamry-endpoint-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CELZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630307376","title":"Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome™ Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2630307376","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630307376?lang=en_us&edition=fundamental","pubTime":"2026-04-28 21:01","pubTimestamp":1777381260,"startTime":"0","endTime":"0","summary":"Ultrasome Demonstrates Strong Clinical Signal While Leveraging GMP-Produced CELZ-201 (Olastrocel) to Target Large, Underserved Osteoarthritis Market PHOENIX, April  28, 2026 (GLOBE NEWSWIRE) -- Creati","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/28/3282769/0/en/Creative-Medical-Technology-Holdings-Inc-Reports-Breakthrough-93-Response-Rate-in-Ultrasome-Knee-Osteoarthritis-Program-Expanding-CELZ-201-Platform-into-Scalable-Cell-Free-Regenera.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621754562","title":"Creative Medical Technology FY 2025 net loss rises 9% to USD 6 million on revenue down 46% to USD 6,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2621754562","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621754562?lang=en_us&edition=fundamental","pubTime":"2026-03-21 04:46","pubTimestamp":1774039589,"startTime":"0","endTime":"0","summary":"Creative Medical Technology Holdings published its annual report on Form 10-K, reporting gross revenue of USD 6,000, down 46% due to a slight decrease in CaverStem sales.Cost of goods sold was USD 2,194, down 50%, and gross profit was USD 3,806, down 42%.Selling, general and administrative expenses rose 16% to USD 3.76 million, driven mainly by higher salaries tied to bonus timing and increased marketing expense.Net loss was USD 6.0 million, while cash and certificates of deposit totaled USD 7.21 million; management said it expects sufficient cash to fund operations through at least March 2027.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Creative Medical Technology Holdings Inc. published the original content used to generate this n","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260320:nNDL83Vnbx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618961582","title":"Creative Medical Technology Holdings Inc  expected to post a loss of 37 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2618961582","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618961582?lang=en_us&edition=fundamental","pubTime":"2026-03-11 04:47","pubTimestamp":1773175625,"startTime":"0","endTime":"0","summary":"Creative Medical Technology Holdings Inc  expected to post a loss of37cents a share - Earnings Preview Creative Medical Technology Holdings Inc CELZ.OQ CELZ.O is expected to  show a fall in quarterly ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nL8N3ZY2M4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610462455","title":"BRIEF-Creative Medical Technology Holdings Achieves Second Who Inn Milestone","url":"https://stock-news.laohu8.com/highlight/detail?id=2610462455","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610462455?lang=en_us&edition=fundamental","pubTime":"2026-02-10 23:50","pubTimestamp":1770738615,"startTime":"0","endTime":"0","summary":"BRIEF-Creative Medical Technology Holdings Achieves Second Who Inn MilestoneFeb 10 (Reuters) - Creative Medical Technology Holdings Inc CELZ.O:CREATIVE MEDICAL TECHNOLOGY HOLDINGS ACHIEVES SECOND WHO ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nFWN3Z60OC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610626839","title":"Creative Medical Technology Holdings Achieves Second Who Inn Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2610626839","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610626839?lang=en_us&edition=fundamental","pubTime":"2026-02-10 22:14","pubTimestamp":1770732860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nFWN3Z60OC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CELZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610662514","title":"Creative Medical Technology Holdings Achieves Second WHO INN Milestone for Cell Therapy Pipeline","url":"https://stock-news.laohu8.com/highlight/detail?id=2610662514","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610662514?lang=en_us&edition=fundamental","pubTime":"2026-02-10 22:00","pubTimestamp":1770732019,"startTime":"0","endTime":"0","summary":"Creative Medical Technology Holdings Inc. announced the achievement of its second International Nonproprietary Name  milestone with the World Health Organization , marking further regulatory progress in its cell therapy pipeline. The WHO has published the proposed INN \"etaroleucel\" for CELZ-101, the company's autologous regulatory T-cell immunotherapy program, which is now entering the formal objection period prior to final confirmation. Additionally, CELZ-201  is also progressing through internationally recognized regulatory pathways. This recognition by the WHO is essential for global clinical development, regulatory alignment, and potential commercialization of the company’s therapies. No other beneficiary organizations were mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inte","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDLb1hBdV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","BK4588","CELZ","LU2210149790.SGD","NDAQ","SG9999014021.USD","BK4585","SG9999014013.SGD","BK4139","IE00B64PRP62.GBP","LU2095319765.USD","SG9999014005.SGD","LU0314104364.USD","LU2210150020.SGD","SG9999014039.USD","IE00BKPKM429.USD","IE00BGHQF748.EUR","BK4112"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603803036","title":"Creative Medical Technology Reports Positive Interim Results for CELZ-201 in Chronic Lower Back Pain Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2603803036","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603803036?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:15","pubTimestamp":1768313713,"startTime":"0","endTime":"0","summary":"Creative Medical Technology Holdings Inc. announced positive interim 180-day follow-up data from its FDA-cleared ADAPT clinical trial evaluating CELZ-201 , a perinatal tissue-derived cell therapy for chronic lower back pain associated with degenerative disc disease. The interim results, which have already been presented, demonstrated statistically significant improvements in functional disability and pain reduction, with approximately 79% of patients achieving clinically meaningful improvement in both areas. An independent Data Safety Monitoring Board review confirmed no serious adverse events and no treatment-related safety signals. The company indicated plans for late-stage regulatory engagement, strategic partnership discussions, and commercialization pending final data.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nNDLb2lhyq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014039.USD","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210149790.SGD","NDAQ","SG9999014013.SGD","SG9999014005.SGD","IE00BGHQF748.EUR","CELZ","IE00BKPKM429.USD","LU0314104364.USD","SG9999014021.USD","BK4139","BK4112","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603680316","title":"Creative Medical Technology Holdings Reaches Major Clinical Inflection Point With Positive Interim Data From Adapt Trial and Celz-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain","url":"https://stock-news.laohu8.com/highlight/detail?id=2603680316","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603680316?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:15","pubTimestamp":1768313700,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260113:nTUA6PGJTL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","CELZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601813826","title":"Creative Medical Technology Holdings Secures Regulatory Approval for Burn Pit Initiative","url":"https://stock-news.laohu8.com/highlight/detail?id=2601813826","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601813826?lang=en_us&edition=fundamental","pubTime":"2026-01-06 22:15","pubTimestamp":1767708908,"startTime":"0","endTime":"0","summary":"Creative Medical Technology Holdings Inc. has received regulatory approval to proceed with its BioDefense Inc. Burn Pit Initiative. This approval allows the company to advance a national program aimed at addressing the long-term health effects of toxic burn pit exposure among U.S. military veterans. The initiative will leverage AI-driven molecular modeling and regenerative medicine technologies, including the company’s proprietary induced pluripotent stem cell  platform. Notably, Creative Medical Technology Holdings confirmed that no additional fundraising is required for this project, as it will be supported by existing partnerships, infrastructure, and vendor relationships.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Creative Medi","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL3SC5Zf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","CELZ","BK4139","LU0314104364.USD","BK4588","NDAQ","SG9999014005.SGD","SG9999014013.SGD","BK4585","IE00BKPKM429.USD","LU2210150020.SGD","IE00B64PRP62.GBP","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014021.USD","LU2210149790.SGD","SG9999014039.USD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592153197","title":"Creative Medical Technology Holdings Inc. Held Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2592153197","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592153197?lang=en_us&edition=fundamental","pubTime":"2025-12-20 05:02","pubTimestamp":1766178157,"startTime":"0","endTime":"0","summary":"Creative Medical Technology Holdings Inc. held its 2025 Annual Meeting of Stockholders on December 18, 2025. At the meeting, all nominated directors were elected to the board. Stockholders approved the compensation of the company's named executive officers. The appointment of Haynie & Company as the company's independent registered public accountants was also ratified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Creative Medical Technology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 19, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251219:nNDL9qpbhJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592915477","title":"BRIEF-Creative Medical Technology Completes Enrollment In FDA-Cleared Adapt Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592915477","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592915477?lang=en_us&edition=fundamental","pubTime":"2025-12-17 22:29","pubTimestamp":1765981767,"startTime":"0","endTime":"0","summary":"BRIEF-Creative Medical Technology Completes Enrollment In FDA-Cleared Adapt TrialDec 17 (Reuters) - Creative Medical Technology Holdings Inc CELZ.O:CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. COMPLETES","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUABM5TLG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592915876","title":"Creative Medical Technology Holdings Completes Enrollment in FDA-Cleared CELZ-201 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2592915876","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592915876?lang=en_us&edition=fundamental","pubTime":"2025-12-17 22:15","pubTimestamp":1765980922,"startTime":"0","endTime":"0","summary":"Creative Medical Technology Holdings Inc. has announced the successful completion of patient enrollment in its FDA-cleared ADAPT clinical trial for CELZ-201 , a proprietary perinatal tissue-derived cell therapy targeting chronic lower back pain associated with degenerative disc disease. The company reported that a positive safety review by an independent Data Safety Monitoring Board found no significant adverse events, supporting the continued advancement of the trial. Topline safety and efficacy results have not yet been presented and are expected in the future as the company advances toward later-stage development and potential commercialization.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Creative Medical Technology Holdings Inc.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nNDLbRXVFZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","IE00BGHQF748.EUR","BK4139","LU2095319765.USD","LU2210150020.SGD","SG9999014021.USD","SG9999014039.USD","SG9999014005.SGD","IE00BKPKM429.USD","NDAQ","BK4588","IE00B64PRP62.GBP","LU2210149790.SGD","CELZ","LU0314104364.USD","SG9999014013.SGD","IE00B3QW5Z07.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592591582","title":"Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared Adapt Trial for Celz-201-Olastrocel, Marking Major Clinical Inflection Point","url":"https://stock-news.laohu8.com/highlight/detail?id=2592591582","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592591582?lang=en_us&edition=fundamental","pubTime":"2025-12-17 22:15","pubTimestamp":1765980900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251217:nTUABM5TLG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CELZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588059611","title":"BRIEF-Creative Medical Technology Holdings Announces World Health Organization Approval Of “Olastrocel”","url":"https://stock-news.laohu8.com/highlight/detail?id=2588059611","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588059611?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:16","pubTimestamp":1764684975,"startTime":"0","endTime":"0","summary":"BRIEF-Creative Medical Technology Holdings Announces World Health Organization Approval Of “Olastrocel” Dec 2 (Reuters) - Creative Medical Technology Holdings Inc CELZ.O:CREATIVE MEDICAL TECHNOLOGY HO","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA8TVMXQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588059659","title":"Creative Medical Technology Holdings Announces World Health Organization Approval of “Olastrocel” as Inn for Lead Allogeneic Cell Therapy Celz-201","url":"https://stock-news.laohu8.com/highlight/detail?id=2588059659","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588059659?lang=en_us&edition=fundamental","pubTime":"2025-12-02 22:15","pubTimestamp":1764684900,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUA8TVMXQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CELZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2582320683","title":"Creative Medical Technology Holdings Awards CEO $100,000 Bonus and CFO $25,000 Bonus","url":"https://stock-news.laohu8.com/highlight/detail?id=2582320683","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582320683?lang=en_us&edition=fundamental","pubTime":"2025-11-12 19:13","pubTimestamp":1762946023,"startTime":"0","endTime":"0","summary":"Creative Medical Technology Holdings Inc. has approved bonuses for two of its top executives. Timothy Warbington, Chief Executive Officer, will receive a bonus of $100,000, while Donald Dickerson, Chief Financial Officer, will receive a bonus of $25,000. The bonuses were approved by the company's Compensation Committee on November 6, 2025.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Creative Medical Technology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 12, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nNDL7HnZPz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CELZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581876742","title":"Creative Medical Technology Holdings Inc  expected to post a loss of 48 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581876742","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581876742?lang=en_us&edition=fundamental","pubTime":"2025-11-05 05:49","pubTimestamp":1762292943,"startTime":"0","endTime":"0","summary":"Creative Medical Technology Holdings Inc  expected to post a loss of48cents a share - Earnings Preview Creative Medical Technology Holdings Inc CELZ.OQ CELZ.O is expected to  show no change in quarter","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251104:nL8N3WG3CH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2580041549","title":"Creative Medical Technology Holdings Raises $4.2 Million Through Warrant Exercises and Issues New Warrants","url":"https://stock-news.laohu8.com/highlight/detail?id=2580041549","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580041549?lang=en_us&edition=fundamental","pubTime":"2025-11-01 04:06","pubTimestamp":1761941179,"startTime":"0","endTime":"0","summary":"Creative Medical Technology Holdings Inc. entered into agreements with holders of warrants to purchase a total of 1,116,136 shares of its common stock at $3.75 per share, generating approximately $4.2 million in gross proceeds. In exchange for exercising these existing warrants, the holders will receive new inducement warrants to purchase an additional 2,790,340 shares of common stock. Roth Capital Partners, LLC acted as financial advisor on the transaction.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Creative Medical Technology Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nNDLcgXT9b:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CELZ","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.creativemedicaltechnology.com","stockEarnings":[{"period":"1week","weight":-0.0482},{"period":"1month","weight":0.0568},{"period":"3month","weight":0.085},{"period":"6month","weight":-0.225},{"period":"1year","weight":0.085},{"period":"ytd","weight":0.1071}],"compareEarnings":[{"period":"1week","weight":0.004},{"period":"1month","weight":0.0948},{"period":"3month","weight":0.0413},{"period":"6month","weight":0.0597},{"period":"1year","weight":0.2669},{"period":"ytd","weight":0.0529}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Creative Medical Technology Holdings, Inc., a commercial stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; and StemSpine, a regenerative stem cell procedure to treat degenerative disc disease. It also develops ImmCelz, an immunotherapy platform for multiple diseases; OvaStem for treatment of female infertility; CELZ-201 to treat Type 1 diabetes; AlloStemSpine for the treatment of chronic lower back pain; and Alova to treat infertility as a result of premature ovarian failure. In addition, the company develops products and services for various indications, including preventing the rejection of transplanted organs, kidney failure, liver failure, heart attack, and Parkinson's disease. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.","yearOnYearQuotes":[{"month":1,"riseRate":0.444444,"avgChangeRate":-0.042115},{"month":2,"riseRate":0.3,"avgChangeRate":0.025647},{"month":3,"riseRate":0.4,"avgChangeRate":0.201188},{"month":4,"riseRate":0.545455,"avgChangeRate":4.203257},{"month":5,"riseRate":0.090909,"avgChangeRate":-0.227991},{"month":6,"riseRate":0.5,"avgChangeRate":0.269879},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.06871},{"month":8,"riseRate":0.3,"avgChangeRate":-0.094834},{"month":9,"riseRate":0.222222,"avgChangeRate":-0.204413},{"month":10,"riseRate":0.111111,"avgChangeRate":-0.124412},{"month":11,"riseRate":0.111111,"avgChangeRate":-0.209338},{"month":12,"riseRate":0.222222,"avgChangeRate":1.583431}],"exchange":"NASDAQ","name":"Creative Medical Technology Holdings, Inc.","nameEN":"Creative Medical Technology Holdings, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Creative Medical Technology Holdings, Inc.(CELZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Creative Medical Technology Holdings, Inc.(CELZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Creative Medical Technology Holdings, Inc.,CELZ,Creative Medical Technology Holdings, Inc.股票,Creative Medical Technology Holdings, Inc.股票老虎,Creative Medical Technology Holdings, Inc.股票老虎国际,Creative Medical Technology Holdings, Inc.行情,Creative Medical Technology Holdings, Inc.股票行情,Creative Medical Technology Holdings, Inc.股价,Creative Medical Technology Holdings, Inc.股市,Creative Medical Technology Holdings, Inc.股票价格,Creative Medical Technology Holdings, Inc.股票交易,Creative Medical Technology Holdings, Inc.股票购买,Creative Medical Technology Holdings, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Creative Medical Technology Holdings, Inc.(CELZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Creative Medical Technology Holdings, Inc.(CELZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}